BiotechTube
Home/Gero/Maxim Kholin
MK

Maxim Kholin

Chief Corporate Development Officer, Co‑Founder

Gero

Therapeutic Areas

AgingFibrosisNeurodegeneration

Gero Pipeline

DrugIndicationPhase
ProtoBind‑Diff Antibody CandidatesSystemic Aging / ResiliencePreclinical
Fibrosis Target ProgramFibrotic DiseasesPreclinical
Chugai Co‑Development AntibodyAge‑Related Immune DysfunctionPreclinical

Leadership Team at Gero

PF
Peter Fedichev, PhD
CEO, Co‑Founder
AS
Aleksandr Sviridov
Chief Operating Officer
BK
Brian Kennedy, PhD
Independent Director, Board Member
YM
Yuri Melnichek
Board Member
VG
Vadim Gladyshev, PhD
Scientific Advisor
View full Gero profile